ADDF, Alzheimer’s Culture partner to provide funding for analysis in Alzheimer’s disease Research to spotlight Repurposing Drugs for Alzheimer's Disease and Related Dementias Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Culture announced a new partnership that will provide funding for analysis in Alzheimer's disease and related dementias, with the purpose of accelerating critical development programs and bringing new treatments to individuals. The partnership intends to fund projects up to $1 Click here .5 million each centered on drug repurposing, leveraging existing scientific research and evidence to accelerate the drug development process. ‘This partnership exemplifies the need for combining and leveraging obtainable resources to accelerate medication discovery in Alzheimer's.’ With nearly 44 million people suffering from Alzheimer's and related diseases worldwide, and the quantity exponentially increasing, the organizations hope to propel promising medication developments into final phases of assessment and ultimately in the hands of these affected by these devastating diseases.
Advancell, Barcelona, Spain, can be a leader in nanomedicine and providers and reagents in both ADME/Tox and Skin Biology areas, including cell-based assays. Advancell’s business model allows it to attain reductions in costs, dangers and the development period of a drug. Their most successful product to date is the CacoReady Program. ADVANCELL operates throughout three divisions: Advancell Therapeutics, which is targeted on development of fresh pharmaceutical software of known molecules through innovative testing; Advancell Alternative Screening, which uses in-vitro methods to predict cell performance, security, and the system of molecule advancement, and Advancell Nanosystems, which uses nano-medicine to treat and prevent illnesses. Advancell offers three different research centers in Spain. And..